Even as epharmacy startup PharmEasy has decided to postpone its IPO plan to next year, the company is cutting burn and has set an interval target to turn Ebitda breakeven in a year, people in the know said. Ebitda, or earnings before interest, taxes, depreciation, and amortization, is a measure of profitability to net income and has become a major focus area for technology startups and investors as a funding slowdown has hit the sector globally.
PharmEasy delays IPO, targets Ebitda breakeven by next year
